IFP Advisors, Inc - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 1 filers reported holding CRISPR THERAPEUTICS AG in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
IFP Advisors, Inc ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$14,389
-70.7%
317
-60.3%
0.00%0.0%
Q2 2023$49,184
+80.9%
798
+97.0%
0.00%0.0%
Q1 2023$27,188
+41093.9%
405
-47.8%
0.00%
-50.0%
Q4 2022$66
-99.9%
776
-29.3%
0.00%0.0%
Q3 2022$88,000
-4.3%
1,098
-7.0%
0.00%
-33.3%
Q2 2022$92,000
-37.4%
1,181
-40.7%
0.00%
+50.0%
Q1 2022$147,000
+153.4%
1,993
+158.8%
0.00%
+100.0%
Q4 2021$58,000
-30.1%
770
+4.1%
0.00%
-50.0%
Q3 2021$83,000
-37.6%
740
-10.1%
0.00%
-33.3%
Q2 2021$133,000
+27.9%
823
-3.6%
0.00%
+50.0%
Q1 2021$104,000
-14.0%
854
+7.2%
0.00%
-60.0%
Q4 2020$121,000
+77.9%
797
-2.9%
0.01%
+25.0%
Q3 2020$68,000
+41.7%
821
+30.1%
0.00%0.0%
Q2 2020$48,000
+77.8%
631
+2.4%
0.00%
+33.3%
Q1 2020$27,000
+237.5%
616
+431.0%
0.00%
+200.0%
Q4 2019$8,000
+33.3%
116
-17.1%
0.00%
Q3 2019$6,000
+500.0%
140
+250.0%
0.00%
Q1 2019$1,000
-94.7%
40
-94.4%
0.00%
-100.0%
Q4 2018$19,000
-38.7%
720
+2.1%
0.00%0.0%
Q3 2018$31,000
-38.0%
705
-17.4%
0.00%
-50.0%
Q2 2018$50,000
+455.6%
853
+113.2%
0.00%
Q1 2018$9,0000.0%4000.0%0.00%
Q4 2017$9,000
+800.0%
400
+900.0%
0.00%
Q1 2016$1,000400.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2016
NameSharesValueWeighting ↓
Versant Venture Management, LLC 3,608,874$160,053,562,00054.44%
Abingworth LLP 1,237,202$54,858,00032.62%
NEA Management Company, LLC 2,090,678$92,722,0004.00%
New Leaf Venture Partners, L.L.C. 444,708$19,723,0003.59%
EcoR1 Capital, LLC 500,000$22,175,0002.00%
ARK Investment Management 1,453,590$64,467,0001.95%
CLOUGH CAPITAL PARTNERS L P 337,731$14,978,0001.41%
Casdin Capital, LLC 220,000$9,757,0001.19%
Valiant Capital Management, L.P. 271,700$12,050,0001.07%
Monashee Investment Management LLC 110,000$4,879,0001.03%
View complete list of CRISPR THERAPEUTICS AG shareholders